

(Under Corporate Insolvency resolution Process)

April 11, 2018

BSE Limited
Corporate Relationship Department
1st floor, New Trading Ring
Rotunda Building, P J Towers
Dalal Street, Fort, Mumbai - 400 001

Sub: Notification as per Listing Regulations – Unaudited Financial Results for the quarter ending December 31, 2017 & Trading Window Closure

Dear Sir/Madam,

We had in our earlier communications informed that Corporate Insolvency Resolution Process (CIRP) has been initiated for "Orchid Pharma Limited" (the Company) under the provisions of the Insolvency and Bankruptcy Code, 2016 ('Code') vide an order of the Honourable National Company Law Tribunal with effect from 17 August, 2017. Pursuant to the initiation of the CIRP, the Powers of the Board of Directors of the Company stands suspended and the management of the affairs of the Company is vested with the Resolution Professional.


Pursuant to Regulation 29 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Resolution Professional shall hold a Meeting on Tuesday, April 17, 2018, inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended 31st December 2017 (Q3 of FY 2017-2018)

Also, the trading window for dealing in the securities of the Company shall remain closed for all the insiders from April 11, 2018 to April 19, 2018 (both days inclusive).

Kindly take the above on your records.

Thanking you,

Yours faithfully,



L Chandrasekar

Executive V P – Finance & Secretary